{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:55:52Z","timestamp":1793890552050,"version":"4.8.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.autrev.2025.103818","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:13:04Z","timestamp":1745233984000},"page":"103818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials"],"prefix":"10.1016","volume":"24","author":[{"given":"Nazila","family":"Heidari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eghbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homayoun","family":"Pishraft-sabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Hajikarim-Hamedani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yekta","family":"Ghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2025.103818_bb0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10103-024-04077-0","article-title":"Efficacy and safety of radiofrequency in the treatment of hidradenitis suppurativa; a systematic review","volume":"39","author":"Nilforoushzadeh","year":"2024","journal-title":"Lasers Med Sci"},{"issue":"8","key":"10.1016\/j.autrev.2025.103818_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082094","article-title":"Hidradenitis Suppurativa: where we are and where we are going","volume":"10","author":"Scala","year":"2021","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.autrev.2025.103818_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179716","article-title":"Immunomodulatory drugs in the treatment of hidradenitis suppurativa-possibilities and limitations","volume":"23","author":"\u015awierczewska","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.autrev.2025.103818_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073753","article-title":"New and emerging targeted therapies for hidradenitis suppurativa","volume":"23","author":"Markota \u010cagalj","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103818_bb0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/CCID.S402453","article-title":"Incidence, risk factors, and prognosis of hidradenitis suppurativa across the globe: insights from the literature","volume":"16","author":"Alotaibi","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103818_bb0030","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjd.19435","article-title":"The epidemiology of hidradenitis suppurativa","volume":"183","author":"Ingram","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2025.103818_bb0035","article-title":"Polygenic score: a tool for evaluating the genetic background of sporadic hidradenitis Suppurativa","author":"Moltrasio","year":"2024","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103818_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/genes15010038","article-title":"Unraveling the epigenetic tapestry: decoding the impact of epigenetic modifications in hidradenitis suppurativa pathogenesis","volume":"15","author":"Nardacchione","year":"2024","journal-title":"Genes"},{"issue":"21","key":"10.1016\/j.autrev.2025.103818_bb0045","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186744","article-title":"Hidradenitis suppurativa: key insights into treatment success and failure","volume":"134","author":"van Straalen","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103818_bb0050","first-page":"53","article-title":"Systematic review of immunomodulatory therapies for hidradenitis suppurativa","volume":"13","author":"Lim","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.autrev.2025.103818_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319851640","article-title":"TNF-alpha inhibitors in the treatment of hidradenitis suppurativa","volume":"10","author":"Savage","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103818_bb0060","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103818_bb0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archdermatol.2011.315","article-title":"Hidradenitis suppurativa: the role of deficient cutaneous innate immunity","volume":"148","author":"Dr\u00e9no","year":"2012","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103818_bb0070","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103818_bb0075","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2133.2011.10698.x","article-title":"Adalimumab (antitumour necrosis factor-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study","volume":"166","author":"van der Zee","year":"2012","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103818_bb0080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/exd.12487","article-title":"Cellular sources of IL-17 in psoriasis: a paradigm shift?","volume":"23","author":"Keijsers","year":"2014","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103818_bb0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajpath.2012.03.044","article-title":"Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies","volume":"181","author":"Maddur","year":"2012","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103818_bb0090","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2025.103818_bb0095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s13671-013-0064-8","article-title":"Epidemiology of hidradenitis suppurativa: prevalence, pathogenesis, and factors associated with the development of HS","volume":"3","author":"Deckers","year":"2014","journal-title":"Curr Dermatol Rep"},{"issue":"3","key":"10.1016\/j.autrev.2025.103818_bb0100","article-title":"Rethinking hidradenitis suppurativa management: insights into bacterial interactions and treatment evolution","volume":"13","author":"Huynh","year":"2024","journal-title":"Antibiotics (Basel)"},{"issue":"10476","key":"10.1016\/j.autrev.2025.103818_bb0105","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat","year":"2025","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.autrev.2025.103818_bb0110","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1097\/DSS.0000000000003235","article-title":"Improvement in quality of life and pain in patients with hidradenitis suppurativa after wide local excision: a prospective study","volume":"47","author":"Dick","year":"2021","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.autrev.2025.103818_bb0115","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2025.103818_bb0120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","article-title":"Biologics for hidradenitis suppurativa: evolution of the treatment paradigm","volume":"20","author":"Maronese","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103818_bb0125","unstructured":"Secukinumab. European Medicines Agency (EMA) summary of product characteristics. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf (Accessed on June 06, 2023)."},{"issue":"10378","key":"10.1016\/j.autrev.2025.103818_bb0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103818_bb0135","series-title":"FDA approval for Bimzelx (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate-to-severe hidradenitis suppurativa","author":"UCB receives U.S","year":"2024"},{"issue":"10443","key":"10.1016\/j.autrev.2025.103818_bb0140","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103818_bb0145","series-title":"Quality assessment of clinical trials","author":"National Heart L, and Blood Institute","year":"2014"},{"key":"10.1016\/j.autrev.2025.103818_bb0150","series-title":"Quality assessment tool for before-after (pre-post) studies with no control group","author":"National Heart L, and Blood Institute","year":"2014"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2025.103818_bb0155","first-page":"5","article-title":"Abstracts of the 8th European Hidradenitis Suppurativa Foundation (EHSF) Conference, 6-8 February 2019, Wroclaw","volume":"28","author":"Becherel","year":"2019","journal-title":"Poland Exp Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103818_bb0160","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/bjd\/ljae098","article-title":"Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials","volume":"190","author":"Zouboulis","year":"2024","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103818_bb0165","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2025.103818_bb0170","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.5278","article-title":"Drug survival of anti interleukin-17 and interleukin \u221223 agents after adalimumab failure in hidradenitis suppurativa: a pilot study","volume":"103","author":"Repetto","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103818_bb0175","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.17822","article-title":"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa","volume":"181","author":"Prussick","year":"2019","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103818_bb0180","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103818_bb0185","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ajd.14267","article-title":"Brodalumab for moderate-severe hidradenitis suppurativa: an open-label multicentric cohort study in real clinical practice","volume":"65","author":"Osorio-G\u00f3mez","year":"2024","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103818_bb0190","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.19478","article-title":"Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study","volume":"184","author":"Frew","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2025.103818_bb0195","author":"Hidradenitis Suppurativa Phase 2b Study of Izokibep"},{"key":"10.1016\/j.autrev.2025.103818_bb0200","author":"Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep"},{"key":"10.1016\/j.autrev.2025.103818_bb0205","author":"MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody\u00ae sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa"},{"issue":"10","key":"10.1016\/j.autrev.2025.103818_bb0210","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1111\/jdv.19252","article-title":"Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized study","volume":"37","author":"Kimball","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103818_bb0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/bjd\/ljad010","article-title":"Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study","volume":"188","author":"Dudink","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103818_bb0220","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103818_bb0225","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","article-title":"Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial","volume":"13","author":"Kimball","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"10.1016\/j.autrev.2025.103818_bb0230","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1alpha for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103818_bb0235","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain","volume":"140","author":"Gottlieb","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103818_bb0240","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ced.14333","article-title":"MABp1 targeting interleukin-1alpha in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period","volume":"46","author":"Kanni","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103818_bb0245","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103818_bb0250","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2025.103818_bb0255","unstructured":"Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3. 2025."},{"issue":"4","key":"10.1016\/j.autrev.2025.103818_bb0260","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/bjd\/ljae144","article-title":"Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial","volume":"191","author":"Alavi","year":"2024","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103818_bb0265","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103818_bb0270","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/bjd\/ljac096","article-title":"Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies","volume":"188","author":"Schell","year":"2023","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103818_bb0275","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103818_bb0280","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.autrev.2025.103818_bb0285","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-H\u00e4ndel","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2025.103818_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103818_bb0295","doi-asserted-by":"crossref","DOI":"10.1177\/20406223241257342","article-title":"Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective","volume":"15","author":"Heidari","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.autrev.2025.103818_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111435","article-title":"A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for hidradenitis suppurativa treatment","volume":"127","author":"Heidari","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103818_bb0305","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/jdv.19770","article-title":"Orismilast for the treatment of mild to severe hidradenitis suppurativa: week 16 data from OSIRIS, a phase 2a, open-label, single-centre, single-arm, dose-finding clinical trial","volume":"38","author":"Frederiksen","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103818_bb0310","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40259-024-00687-w","article-title":"Interleukin-17 inhibitors in the treatment of hidradenitis suppurativa","volume":"39","author":"Pinto Salgueiro","year":"2025","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.autrev.2025.103818_bb0315","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103818_bb0320","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2025.103818_bb0325","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.2147\/CCID.S418748","article-title":"Guselkumab, risankizumab, and tildrakizumab in the management of hidradenitis suppurativa: a review of existing trials and real-life data","volume":"16","author":"Martora","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103818_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/biom14020175","article-title":"Therapeutic potential of IL-1 antagonism in hidradenitis suppurativa","volume":"14","author":"Calabrese","year":"2024","journal-title":"Biomolecules"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:05:45Z","timestamp":1762553145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1568997225000783"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103818","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103818"}}